|Bid||0.00 x 145200|
|Ask||0.00 x 140700|
|Day's range||18.83 - 19.45|
|52-week range||14.81 - 31.24|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||28 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemiaiPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluationT1D preclinical models with iPSC derived islet clusters transplanted in Sernova’s Cell Pouch has now demonstrated co
To get a sense of who is truly in control of Evotec SE ( ETR:EVT ), it is important to understand the ownership...
Last week saw the newest quarterly earnings release from Evotec SE ( ETR:EVT ), an important milestone in the company's...